الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

rising pharma holdings, inc. - diflorasone diacetate (unii: 7w2j09scwx) (diflorasone - unii:t2dhj9645w) - topical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical steroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

laboratories gerda - amorolfine hydrochloride - medicated nail lacquer - 5 percent weight/volume - amorolfine

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

genentech, inc. - vemurafenib (unii: 207smy3fqt) (vemurafenib - unii:207smy3fqt) - vemurafenib 240 mg - zelboraf® is indicated for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fda-approved test. limitation of use: zelboraf is not indicated for treatment of patients with wild-type braf melanoma [see warnings and precautions (5.2)] . zelboraf® is indicated for the treatment of patients with erdheim-chester disease (ecd) with braf v600 mutation. none. risk summary based on its mechanism of action, zelboraf can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data on the use of zelboraf in pregnant women to determine the drug-associated risk; however, placental transfer of vemurafenib to a fetus has been reported. exposure to vemurafenib could not be achieved in animals at levels sufficient to fully address its potential toxicity in pregnant women. advise pregnant women of the potential harm to a fetus. the estimated background risks of major birth defects and miscarriage for the indicated population(s) are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. data animal data vemurafenib showed no evidence of developmental toxicity in rat fetuses at doses up to 250 mg/kg/day (approximately 1.3 times the clinical exposure at 960 mg twice daily based on auc) or rabbit fetuses at doses up to 450 mg/kg/day (approximately 0.6 times the clinical exposure at 960 mg twice daily based on auc). fetal drug levels were 3–5% of maternal levels, indicating that vemurafenib has the potential to be transmitted from the mother to the developing fetus. there is no information available regarding the presence of vemurafenib in human milk, effects on the breastfed infant, or effects on milk production. because of the potential for serious adverse reactions in a breastfed infant, including malignancy, severe dermatologic reactions, qt prolongation, hepatotoxicity, photosensitivity, and ophthalmologic toxicity, [see warnings and precautions (5)] , advise women not to breastfeed during treatment with zelboraf and for 2 weeks after the final dose. contraception based on its mechanism of action, zelboraf can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)] . advise females of reproductive potential to use effective contraception during treatment with zelboraf and for 2 weeks after the final dose. the safety and effectiveness of zelboraf in pediatric patients have not been established. vemurafenib was studied in 6 adolescent patients 15 to 17 years of age with unresectable or metastatic melanoma with braf v600 mutation. a maximum tolerated dose was not reached with doses up to vemurafenib 960 mg twice daily. no new safety signals were observed. vemurafenib steady-state exposure in these 6 adolescent patients was generally similar to that in adults. clinical studies of zelboraf did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. no formal clinical study has been conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of vemurafenib. no dose adjustment is recommended for patients with mild and moderate hepatic impairment based on a population pharmacokinetic analysis [see clinical pharmacology (12.3)]. the appropriate dose of zelboraf has not been established in patients with severe hepatic impairment. no formal clinical study has been conducted to evaluate the effect of renal impairment on the pharmacokinetics of vemurafenib. no dose adjustment is recommended for patients with mild and moderate renal impairment based on a population pharmacokinetic analysis [see clinical pharmacology (12.3)]. the appropriate dose of zelboraf has not been established in patients with severe renal impairment.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

church & dwight co., inc. - passiflora incarnata flowering top (unii: clf5yfs11o) (passiflora incarnata flowering top - unii:clf5yfs11o), turpentine oil (unii: c5h0qj6v7f) (turpentine oil - unii:c5h0qj6v7f), oyster shell calcium carbonate, crude (unii: 2e32821g6i) (oyster shell calcium carbonate, crude - unii:2e32821g6i), matricaria recutita (unii: g0r4ubi2zz) (matricaria recutita - unii:g0r4ubi2zz), arabica coffee bean (unii: 3sw678mx72) (arabica coffee bean - unii:3sw678mx72), tribasic calcium phosphate (unii: 91d9gv0z28) (calcium c - passiflora incarnata flowering top 6 in 1 [hp_x] - calcarea carbonica - delayed or slow teething calcarea phosphorica - difficult teething, dentition chamomilla - irritibility, crying and whining coffea cruda - occassional sleeplessness, restlessness passiflora incarnata - restlessness terebinthia - irritability uses temporarily relieves the multiple symptoms of dentition, restlessness and wakeful irritability due to cutting teeth. for children under 2, consult your physician or healthcare provider.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

pharmaderm a division of fougera pharmaceuticals inc. - diflorasone diacetate (unii: 7w2j09scwx) (diflorasone - unii:t2dhj9645w) - diflorasone diacetate 0.5 mg in 1 g - topical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. topical steroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

seroyal usa - sodium borate (unii: 91mbz8h3qo) (borate ion - unii:44oae30d22) - sodium borate 1 [hp_x] - indications for the temporary relief of motion sickness, nausea, and diarrhea indications for the temporary relief of motion sickness, nausea, and diarrhea directions adults: take five granules three times daily or as recommended by your healthcare practitioner. children: take three granules and follow adult directions.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

standard homeopathic company - sodium borate (unii: 91mbz8h3qo) (borate ion - unii:44oae30d22) - sodium borate 6 [hp_x] in 1 g - skin eruptions or diarrhea

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

energetix corp - azadirachta indica bark (unii: g580b439yi) (azadirachta indica bark - unii:g580b439yi), atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), berberis vulgaris root bark (unii: 1th8q20j0u) (berberis vulgaris root bark - unii:1th8q20j0u), peumus boldus leaf (unii: q4ewm09m3o) (peumus boldus leaf - unii:q4ewm09m3o), candida albicans (unii: 4d7g21hdbc) (candida albicans - unii:4d7g21hdbc), ceanothus americanus leaf (unii: 25b1y14t8n) (ceanothus americanus leaf - unii:25b1y14t8n), ce - azadirachta indica bark 8 [hp_x] in 1 ml - temporary relief of fever, chills, mucus congestion. claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. temporary relief of fever, chills, mucus congestion. claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

energique, inc. - passiflora incarnata flowering top (unii: clf5yfs11o) (passiflora incarnata flowering top - unii:clf5yfs11o), sus scrofa adrenal gland (unii: 398iyq16yv) (sus scrofa adrenal gland - unii:398iyq16yv), thyroid, bovine (unii: mn18otn73w) (thyroid, bovine - unii:mn18otn73w), araneus diadematus (unii: 6t6co7r3z5) (araneus diadematus - unii:6t6co7r3z5), arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), hypericum - passiflora incarnata flowering top 3 [hp_x] in 1 ml - may temporarily relieve numbness and tingling, stiffness in nape of the neck with shooting pain, and tingling and burning pain with numbness.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. may temporarily relieve numbness and tingling, stiffness in nape of the neck with shooting pain, and tingling and burning pain with numbness.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

energetix corp - azadirachta indica bark (unii: g580b439yi) (azadirachta indica bark - unii:g580b439yi), atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), berberis vulgaris root bark (unii: 1th8q20j0u) (berberis vulgaris root bark - unii:1th8q20j0u), peumus boldus leaf (unii: q4ewm09m3o) (peumus boldus leaf - unii:q4ewm09m3o), candida albicans (unii: 4d7g21hdbc) (candida albicans - unii:4d7g21hdbc), ceanothus americanus leaf (unii: 25b1y14t8n) (ceanothus americanus leaf - unii:25b1y14t8n), ce - azadirachta indica bark 8 [hp_x] in 1 ml - temporary relief of fever, diarrhea, swelling, thick colored mucus. temporary relief of fever, diarrhea, swelling, thick colored mucus.